Current treatment approaches for mantle-cell lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 26, 2005, Pages 6409-6414

  Witzig, Thomas E ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CLADRIBINE; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IBRITUMOMAB TIUXETAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; TOSITUMOMAB I 131; VINCRISTINE; ANTINEOPLASTIC AGENT; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; HUMAN; IMMUNOHISTOCHEMISTRY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL TIME; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; PATIENT SELECTION; PREDNISOLONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 27244434474     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.55.017     Document Type: Review

References (53)

1. Andersen NS, Jensen MK, de Nully Brown P, et al: A Danish population-based analysis of 105 mantle cell lymphoma patients: Incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 38:401-408, 2002
2. Kurtin PJ: Mantle cell lymphoma. Adv Anat Pathol 5:376-398, 1998
3. Kurtin PJ, Hobday KS, Ziesmer S, et al: Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry. Am J Clin Pathol 112: 319-329, 1999
4. Bertoni F, Zucca E, Cotter FE: Molecular basis of mantle cell lymphoma. Br J Haematol 124:130-140, 2004
5. Siebert R, Matthiesen P, Harder S, et al: Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol 9:519-526, 1998
6. Caraway NP, Gu J, Lin P, et al: The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14) (q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens. Cancer 105:110-118, 2005
7. Remstein ED, Kurtin PJ, Buno I, et al: Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 110:856-862, 2000
8. Au WY, Gascoyne RD, Viswanatha DS, et al: Cytogenetic analysis in mantle cell lymphoma: A review of 214 cases. Leuk Lymphoma 43:783-791, 2002
9. Bentz JS, Rowe LR, Anderson SR, et al: Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material. Cancer 102:124-131, 2004
10. Rubio-Moscardo F, Climent J, Siebert R, et al: Mantle cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 105:4445-4454, 2005
11. Ghobrial IM, McCormick DJ, Kaufmann SH, et al: Proteomic analysis of mantle cell lymphoma by protein microarray. Blood 105: 3722-3730, 2005
12. Schraders M, Pfundt R, Straatman HM, et al: Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 105:1686-1693, 2005
13. Hanson CA, Kurtin PJ, Katzmann JA, et al: Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood 94:3889-3896, 1999
14. Cohen PL, Kurtin PJ, Donovan KA, et al: Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 101: 302-310, 1998
15. Romaguera JE, Medeiros LJ, Hagemeister FB, et al: Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97:586-591, 2003
16. Zucca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphoma. Ann Oncol 6:257-262, 1995
17. Bosch F, Lopez-Guillermo A, Campo E, et al: Mantle cell lymphoma: Presenting features, response to therapy, and prognostic factors. Cancer 82:567-575, 1998
18. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell sub-categories): A Southwest Oncology Group study. Blood 85:1075-1082, 1995
19. Samaha H, Dumontet C, Ketterer N, et al: Mantle cell lymphoma: A retrospective study of 121 cases. Leukemia 12:1281-1287, 1998
20. Matutes E, Parry-Jones N, Brito-Babapulle V, et al: The leukemic presentation of mantle-cell lymphoma: Disease features and prognostic factors in 58 patients. Leuk Lymphoma 45: 2007-2015, 2004
21. Yoong Y, Kurtin PJ, Allmer C, et al: Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Leuk Lymphoma 42: 1235-1241, 2001
22. Ghielmini M, Schmitz S-FH, Cogliatti S, et al: Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: A study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23:705-711, 2005
23. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
24. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
25. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
26. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005
27. Romaguera JE, Fayad L, Rodriguez MA, et al: Rituximab plus hyperCVAD (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M/A) in untreated mantle cell lymphoma (MCL): Prolonged follow-up confirms high rates of failure-free survival (FFS) and overall survival (OS). Blood 104, 2004 (abstr 128)
28. Decaudin D, Bosq J, Tertian G, et al: Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 16: 579-583, 1998
29. Foran JM, Rohatiner AZ, Coiffier B, et al: Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546-553, 1999
30. Cohen BJ, Moskowitz C, Straus D, et al: Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 42:1015-1022, 2001
31. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004
32. Inwards D, Brown D, Fonseca R, et al: NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as initial therapy for mantle cell lymphoma: A well-tolerated treatment with promising activity. Blood 94:660a, 1999 (suppl 1)
33. Rummel MJ, Chow KU, Karakas T, et al: Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 38:1739-1746, 2002
34. Inwards DJ, Fonseca R, Kurtin PJ, et al: NCCTG phase II trial of 2-chlorodeoxyadenosine (2-CDA) as therapy for previously treated mantle cell lymphoma: Promising single agent activity limited by brief response duration. Blood 96: 140a, 2000
35. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
36. Oki Y, Pro B, Delpassand E, et al: A phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 104, 2004 (abstr 2632)
37. Zelenetz AD, Donnelly G, Halaas J, et al: Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab/iodine I131 I-tositumomab followed by CHOP chemotherapy results in a high complete remission rate. Blood 102, 2003 (abstr 1477)
38. Nachbaur D, Greinix HT, Koller E, et al: Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/ intermediate-grade B non-Hodgkin's lymphoma (NHL): A report from the Austrian Stem Cell Transplantation. Registry (ASCTR). Ann Hematol 23:23, 2005
39. Kasamon YL, Jones RJ, Diehl LF, et al: Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 11:39-46, 2005
40. Lefrere F, Delmer A, Levy V, et al: Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: An update of a prospective study. Haematologica 89:1275-1276, 2004
41. Popplewell LL, Nademanee A, Carter N, et al: Autologous vs allogeneic cell transplantation for mantle cell lymphoma (MCL): Outcomes over a 10-year period at City of Hope. Blood 104, 2004 (abstr 894)
42. Mangel J, Leiten HA, Connors JM, et al: Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: A matched pair analysis. Ann Oncol 15:283-290, 2004
43. Maris MB, Sandmaier BM, Storer BE, et al: Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535-3542, 2004
44. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: Results of a prospective randomized trial of the European MCL network. Blood 105:2677-2684, 2005
45. Gopal AK, Raiendran JG, Petersdorf SH, et al: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 99:3158-3162, 2002
46. Freedman AS, Neuberg D, Gribben JG, et al: High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission. J Clin Oncol 16:13-18, 1998
47. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Stood 102:749-755, 2003
48. Winter JN, Inwards D, Erwin W, et al: Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma. Early outcome results. Blood 100: 411a, 2002 (abstr 1597)
49. Nademanee A, Forman SJ, Molina A, et al: High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial. J Clin Oncol 22:559, 2004 (abstr 6504)
50. Goy A, Younes A, McLaughlin P, et al: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory b-cell non-Hodgkin's lymphoma. J Clin Oncol 23:667-675, 2005
51. O'Connor OA, Wright J, Moskowitz C, et al: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23:676-684, 2005
52. Kaufmann H, Raderer M, Wohrer S, et al: Anti-tumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104:2269-2271, 2004
53. Witzig T, Geyer S, Ghobrial I, et al: Anti-tumor activity of single-agent CCI-779 for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23:5347-5356, 2005